Table 2. Clinical data with figitumumab.
Primary endpoint | P value | |
---|---|---|
Phase II (8) | ||
Carboplatin/paclitaxel/figitumumab | ORR 54% | P<0.0001 (95% CI, 0.44 to 0.64) |
Carboplatin/paclitaxel | ORR 42% | |
Phase III (9) | ||
Carboplatin/paclitaxel/figitumumab | OS 10.3 months | HR 1.23 (95% CI, 1.0-1.5), P=0.051 |
Carboplatin/paclitaxel | OS 8.5 months | |
Phase III (not published) | ||
Figitumumab/erlotinib | OS: terminated for futility | n/a |